Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week
New York, Jan 17, 2026, 10:03 ET — Market closed.
- Eli Lilly shares closed Friday 0.5% higher following a volatile session.
- The FDA has set April 10 as the new target date to decide on Lilly’s experimental weight-loss drug.
- Traders are keeping an eye on early U.S. prescription figures for Novo Nordisk’s new Wegovy pill.
Eli Lilly shares ended Friday up 0.5%, closing at $1,038.40. Investors enter the week anticipating a delayed U.S. regulatory verdict on the drugmaker’s experimental obesity medication.
The key issue now is timing. A postponed verdict on Lilly’s oral weight-loss drug comes amid a rapidly evolving race, where pills aim to expand the market beyond injectable treatments.
This matters…
